Lv5
1580 积分 2023-12-13 加入
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
1个月前
已完结
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
1个月前
已完结
Hepatocellular carcinoma
1个月前
已完结
Immunological pathways in viral hepatitis-induced hepato-cellular carcinoma
1个月前
已完结
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
2个月前
已完结
KRAS inhibitors: resistance drivers and combinatorial strategies
2个月前
已完结
Immunotherapies for hepatocellular carcinoma
3个月前
已完结
Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: Pooled analysis of RAGNAR and LUC2001 studies
4个月前
已完结
Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response (DDR) pathway deficient neoplasms (NCT03207347)
4个月前
已关闭
Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab
4个月前
已完结
皖公网安备34019202002308
